Among the high-quality abstract presentations at the annual San Antonio Breast Cancer Symposium (SABCS), a few always stand out as particularly meritorious. Each year, The ASCO Post asks its Senior Deputy Editor, breast cancer specialist Jame Abraham, MD, FACP, to offer his top picks for most impactful studies. Dr. Abraham is the Enterprise Chair of the Department of Hematology and Medical Oncology and Professor of Medicine at the Cleveland Clinic Lerner College of Medicine.

Each year in the United States, about 90,000 adolescents and young adults (AYAs), ages 15 to 39, are diagnosed with cancer,¹ and they are immediately faced with myriad challenges and disruptions in their life stages, including psychosocial distress; interruptions in their education, career, and social life; body image struggles; and potentially life-altering consequences on fertility. Studies show that between 12% and 88% of AYAs undergoing treatment for cancer, including surgery, chemotherapy, and radiation therapy, experience risk to their fertility.²

Monotherapy with a gemcitabine intravesical system (TAR-200; Gem-iDRS) demonstrated high disease-free survival rates in patients with bacillus Calmette-Guérin (BCG)-unresponsive papillary-only high-risk non–muscle-invasive bladder cancer (NMIBC), according to data presented at the 26th Annual Meeting of the Society of Urologic Oncology (SUO).¹

On February 26, the U.S. Food and Drug Administration (FDA) granted accelerated approval to zongertinib (Hernexeos), a kinase inhibitor, for an expanded indication for adults with unresectable or metastatic nonsquamous non–small cell lung cancer (NSCLC) whose tumors have HER2 tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.